Medical Oncology

, Volume 19, Issue 2, pp 117–119

Flutamide-induced acute renal failure in a patient with metastatic prostate cancer

  • Mehmet Riza Altiparmak
  • Ahmet Bilici
  • Bunyamin Kisacik
  • Mustafa Ozguroglu
Case Report


Androgen blockage, with either orchiectomy or luteinizing hormone releasing hormone (LHRH) analogs combined with an antiandrogen drug, is the standard treatment for metastatic prostate cancer. Flutamide is a nonsteroidal antiandrogen drug that is frequently used for total androgen blockage. We report on a 54-yr-old man with metastatic prostate cancer who developed nonoliguric acute renal failure (ARF) during treatment with flutamide. Following discontinuation of flutamide therapy, his renal functions returned to normal limits within 4 wk. After a rechallenge with flutamide, serum levels of BUN and creatinine increased again. His renal function recovered completely after the cessation of the drug for the second time. This observation confirm that ARF may be clearly attributed to flutamide therapy. Although very rare, flutamide-induced ARF should be considered.

Key Words

Flutamide acute renal failure prostate cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Crawford, E.D., Mario, A., Eisenberger, M.A., David, G., McLeod, D.G., Joseph, T., et al. (1989). A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N. Engl. J. Med. 321:419–424.PubMedCrossRefGoogle Scholar
  2. 2.
    Cetin, M., Demirci, D., Unal, A., Altmbas, M., Guven, M. and Unluhizarci, K. (1999). Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum; Exp. Toxicol. 18:137–140.PubMedCrossRefGoogle Scholar
  3. 3.
    Fossa, D.S., Slee, P.H., Brausi, M., Horenblas, S., Hall, R.R., Hetherigton, J.W., et al. (2001). Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the european organization for research and treatment of cancer genitourinary group. J. Clin. Oncol. 19:62–71.PubMedGoogle Scholar
  4. 4.
    Boccardo, F., Rubagotti, A., Barichello, M., Battaglia, M., Carmignani, G., Comeri, G., et al. (1999). Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer petients: results of an Italian prostate cancer project study. J. Clin. Oncol. 17:2027–2038.PubMedGoogle Scholar
  5. 5.
    Paul, A.B., Love, C. and Chisholm, G.D. (1994). The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer. Br. J. Urol. 74:642–645.PubMedCrossRefGoogle Scholar
  6. 6.
    Smith, A., Harbour, D. and Liebman, J. (1997). Acute renal failure in a patient receiving treatment with suramin. Am. J. Clin. Oncol. 20:433–434.PubMedCrossRefGoogle Scholar
  7. 7.
    Figg, W.D., Cooper, M.R., Thibault, A., Headlee, D., Humphrey, J., Bergan, R.C., et al. (1994). Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer 74:1612–1614.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2002

Authors and Affiliations

  • Mehmet Riza Altiparmak
    • 1
  • Ahmet Bilici
    • 2
  • Bunyamin Kisacik
    • 2
  • Mustafa Ozguroglu
    • 3
  1. 1.Department of Nephrology, Cerrahpasa School of MedicineIstanbul UniversityIstanbulTurkey
  2. 2.Department of Internal Medicine, Cerrahpasa School of MedicineIstanbul UniversityIstanbulTurkey
  3. 3.Department of Medical Oncology, Cerrahpasa School of MedicineIstanbul UniversityIstanbulTurkey
  4. 4.Rasimpasa MahallesiTaslibayir SokakIstanbulTurkey

Personalised recommendations